Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Nøkleby H[au]:

Search results

Items: 1 to 50 of 71

1.

Systematic mapping of checklists for assessing transferability.

Munthe-Kaas H, Nøkleby H, Nguyen L.

Syst Rev. 2019 Jan 14;8(1):22. doi: 10.1186/s13643-018-0893-4.

2.

Bacille Calmette-Guérin vaccination of healthcare personnel: changing epidemiology calls for new recommendations in Norway.

Arnesen TM, Brantsæter AB, Nøkleby H.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801123. doi: 10.1183/13993003.01123-2018. Print 2019 Jan. No abstract available.

PMID:
30630851
3.

Response to third rubella vaccine dose.

Siira L, Nøkleby H, Barlinn R, Riise ØR, Aaberge IS, Dudman SG.

Hum Vaccin Immunother. 2018;14(10):2472-2477. doi: 10.1080/21645515.2018.1475814. Epub 2018 Jun 21.

4.

Supported Employment for People with Disabilities: A Systematic Review [Internet].

Nøkleby H, Blaasvær N, Berg RC.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Mar 30.

5.

What Are the Consequences of Shared Physical Custody for Children? A Systematic Review [Internet].

Blaasvær N, Nøkleby H, Berg RC.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 1.

6.

Effects of Interventions in Residential Areas and Neighbourhoods to Promote Social Contact, Social Networks and Social Support [Internet].

Kurtze N, Nøkleby H, Berg RC.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 Nov.

7.

The Effect of Interventions for At-Risk Families with Children 0-6 Years [Internet].

Blaasvær N, Nøkleby H, Johansen S, Berg RC.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 Nov.

8.

Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian Childhood Immunisation Programme.

Feiring B, Laake I, Molden T, Håberg SE, Nøkleby H, Seterelv SS, Magnus P, Trogstad L.

Vaccine. 2016 Apr 12;34(17):2015-20. doi: 10.1016/j.vaccine.2016.02.060. Epub 2016 Mar 3.

PMID:
26947498
9.

Monitoring of timely and delayed vaccinations: a nation-wide registry-based study of Norwegian children aged < 2 years.

Riise ØR, Laake I, Bergsaker MA, Nøkleby H, Haugen IL, Storsæter J.

BMC Pediatr. 2015 Nov 13;15:180. doi: 10.1186/s12887-015-0487-4.

10.

[Health personnel should be vaccinated!].

Stoltenberg C, Hauge SH, Riise Bergsaker MA, Nøkleby H, Magnus P.

Tidsskr Nor Laegeforen. 2014 Feb 11;134(3):270. doi: 10.4045/tidsskr.14.0085. Norwegian. No abstract available.

11.

Susceptibility to cytomegalovirus, parvovirus B19 and age-dependent differences in levels of rubella antibodies among pregnant women.

Barlinn R, Vainio K, Samdal HH, Nordbø SA, Nøkleby H, Dudman SG.

J Med Virol. 2014 May;86(5):820-6. doi: 10.1002/jmv.23757. Epub 2013 Sep 30.

PMID:
24114849
12.

Risk of fetal death after pandemic influenza virus infection or vaccination.

Håberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK, Samuelsen SO, Skrondal A, Cappelen I, Engeland A, Aavitsland P, Madsen S, Buajordet I, Furu K, Nafstad P, Vollset SE, Feiring B, Nøkleby H, Magnus P, Stoltenberg C.

N Engl J Med. 2013 Jan 24;368(4):333-40. doi: 10.1056/NEJMoa1207210. Epub 2013 Jan 16.

13.

Considerations for controlling invasive meningococcal disease in high income countries.

Holst J, Nøkleby H, Bettinger JA.

Vaccine. 2012 May 30;30 Suppl 2:B57-62. doi: 10.1016/j.vaccine.2011.12.093. Review.

PMID:
22607900
14.

[A woman in her 40s with rash and spots on the oral mucosa].

Larsen S, Nøkleby H, Amundsen D.

Tidsskr Nor Laegeforen. 2012 Mar 6;132(5):534-6. doi: 10.4045/tidsskr.10.1132. Norwegian. No abstract available.

15.

Applicability of evidence-based practice in public health: risk assessment on Q fever under an ongoing outbreak.

Forland F, De Carvalho Gomes H, Nokleby H, Escriva A, Coulombier D, Giesecke J, Jansen A.

Euro Surveill. 2012 Jan 19;17(3):20060. Review.

16.

[The pandemic in Austevoll].

Aavitsland P, Iversen BG, Nøkleby H.

Tidsskr Nor Laegeforen. 2011 Jun 17;131(12):1180. doi: 10.4045/tidsskr.11.0524. Norwegian. No abstract available.

17.

Protection against poliomyelitis in Europe.

Nokleby H, De Carvalho Gomes H, Johansen K, Kreidl P.

Euro Surveill. 2010 Apr 29;15(17). pii: 19556.

19.

Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome.

Magnus P, Brubakk O, Nyland H, Wold BH, Gjessing HK, Brandt I, Eidem T, Nøkleby H, Stene-Larsen G.

Vaccine. 2009 Jan 1;27(1):23-7. doi: 10.1016/j.vaccine.2008.10.043. Epub 2008 Nov 5.

PMID:
18984023
20.
21.

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nøkleby H, Rosenqvist E.

Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. Epub 2007 Jul 18.

22.

[The HPV vaccine--a tested and approved reality].

Klouman E, Nøkleby H.

Tidsskr Nor Laegeforen. 2007 Jun 14;127(12):1674-5. Norwegian. No abstract available.

23.

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P.

Vaccine. 2007 Apr 20;25(16):3080-4. Epub 2007 Jan 22.

PMID:
17287053
24.

[50 years with polio vaccine in Norway].

Flugsrud LB, Nøkleby H.

Tidsskr Nor Laegeforen. 2006 Dec 14;126(24):3251. Norwegian. No abstract available.

25.

Contributions of the Norwegian Institute of Public Health to the development of vaccines against serogroup B meningococcal disease.

Rosenqvist E, Holst J, Nøkleby H.

Vaccine. 2007 Jan 22;25(6):965-6. Epub 2006 Oct 4. No abstract available.

PMID:
17052822
26.

[Adverse events after vaccination].

Nøkleby H, Bergsaker MA.

Tidsskr Nor Laegeforen. 2006 Oct 5;126(19):2541-4. Review. Norwegian.

27.

[The Norwegian vaccination program].

Nøkleby H, Feiring B.

Tidsskr Nor Laegeforen. 2006 Oct 5;126(19):2538-40. Norwegian.

28.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nøkleby H, Aaberge IS.

Clin Vaccine Immunol. 2006 Jul;13(7):790-6.

29.

Vaccination and anaphylaxis.

Nokleby H.

Curr Allergy Asthma Rep. 2006 Feb;6(1):9-13. Review.

PMID:
16476188
30.

[Whooping cough--an old disease of current interest].

Nøkleby H, Kristiansen BE.

Tidsskr Nor Laegeforen. 2006 Jan 26;126(3):295. Norwegian. No abstract available.

31.
32.

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.

Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nokleby H, Rosenqvist E, White K, Reid S, Mulholland K, Wakefield MJ, Martin D.

Vaccine. 2006 Feb 27;24(9):1395-400. Epub 2005 Oct 4.

PMID:
16242221
33.

Prevention of viral hepatitis in the Nordic countries and Germany.

Fitzsimons D, François G, Alpers K, Radun D, Hallauer J, Jilg W, Gerlich W, Rombo L, Blystad H, Nøkleby H, van Damme P.

Scand J Infect Dis. 2005;37(8):549-60. Review.

PMID:
16099768
34.

Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Aaberge IS, Oster P, Helland OS, Kristoffersen AC, Ypma E, Høiby EA, Feiring B, Nøkleby H.

Clin Diagn Lab Immunol. 2005 May;12(5):599-605.

35.

Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.

Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun M, de Souza-Brito G, Davis RL, Halperin S, Heininger U, Khuri-Bulos N, Menkes J, Nokleby H; Brighton Collaboration HHE Working Group.

Vaccine. 2004 Jan 26;22(5-6):563-8. Review. No abstract available.

PMID:
14741145
36.

[Vaccination of persons with allergy].

Nøkleby H.

Tidsskr Nor Laegeforen. 2003 Dec 4;123(23):3400-1. Norwegian. No abstract available.

37.

The conjugate vaccine and invasive pneumococcal disease.

Konradsen HB, Nokleby H.

N Engl J Med. 2003 Aug 14;349(7):714-6; author reply 714-6. No abstract available.

PMID:
12921091
38.

[Will a vaccine save us from SARS?].

Nøkleby H.

Tidsskr Nor Laegeforen. 2003 Jun 26;123(13-14):1818. Norwegian. No abstract available.

PMID:
12830249
39.

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.

Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E.

Vaccine. 2003 Jan 30;21(7-8):734-7.

PMID:
12531351
40.

[Vaccination of immunocompromised patients].

Nøkleby H.

Tidsskr Nor Laegeforen. 2002 Nov 20;122(28):2711-2. Norwegian. No abstract available.

41.

[Young children, pregnant women and travelling abroad].

Sandbu S, Nøkleby H.

Tidsskr Nor Laegeforen. 2002 Jun 20;122(16):1573-6. Norwegian.

42.

[Vaccination, inflammatory bowel disease and autism--is there a connection?].

Nøkleby H.

Tidsskr Nor Laegeforen. 2001 Sep 30;121(23):2679. Norwegian. No abstract available.

43.

[Should school children receive pertussis vaccine?].

Sandbu S, Nøkleby H, Helland OS, Feiring B, Bondevik M, Sundelin F, Storsaeter J.

Tidsskr Nor Laegeforen. 2001 May 10;121(12):1464-8. Norwegian.

44.

[Who is to be vaccinated against rotaviruses?].

Nøkleby H.

Tidsskr Nor Laegeforen. 1999 Oct 30;119(26):3884. Norwegian. No abstract available.

PMID:
10592743
45.

No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine.

Wedege E, Nokleby H, Bjune G.

J Infect Dis. 1999 Jul;180(1):242; author reply 242-3. No abstract available.

PMID:
10353890
46.

Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.

Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, Nøkleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA.

JAMA. 1999 Apr 28;281(16):1520-7.

PMID:
10227322
47.

Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia.

Peltola H, Aavitsland P, Hansen KG, Jónsdóttir KE, Nøkleby H, Romanus V.

J Infect Dis. 1999 Jan;179(1):223-9.

PMID:
9841843
48.

Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.

Rosenqvist E, Høiby EA, Bjune G, Aase A, Halstensen A, Lehmann AK, Paulssen J, Holst J, Michaelsen TE, Nøkleby H, Frøholm LO, Closs O.

Dev Biol Stand. 1998;92:323-33.

PMID:
9554288
49.

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.

Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, Rosenqvist E, Holst J, Nokleby H, Sotolongo F, Sierra G, Campa HC, Carlone GM, Williams D, Dykes J, Kapczynski D, Tikhomirov E, Wenger JD, Broome CV.

J Infect Dis. 1998 Mar;177(3):683-91.

PMID:
9498448
50.

[New pertussis vaccine in the vaccination program].

Nøkleby H.

Tidsskr Nor Laegeforen. 1998 Jan 10;118(1):10. Norwegian. No abstract available.

PMID:
9481899

Supplemental Content

Loading ...
Support Center